AEterna Zentaris Inc. Summary: According to the law firm press release, the complaint alleges that defendants mislead investors about the timing and success of AEterna’s clinical trial that tested whether the drug perifosine was effective in treating late stage colorectal cancer.
On April 2, 2012, AEterna shocked the market by disclosing that perifosine was ineffective in treating colorectal cancer. This news caused AEterna stock to drop approximately 66% by the close of the business day.
On September 4, 2012, the Court issued an Order appointing lead plaintiff and approving the selection of lead counsel.
On November 5, 2012, the Plaintiffs filed an Amended Complaint. On December 21, Plaintiffs followed with a Second Amended Complaint.
SIC Code: 2834
Industry: Biotechnology & Drugs
WARNING AND DISCLAIMER OF LIABILITY:
The information included on this Web site, whether provided by personnel employed by Stanford Law School or by third parties, is provided for research and teaching purposes only. Neither Stanford University, Stanford Law School, nor any of their employees, agents, contractors, or affiliates warrant the accuracy or completeness of the information or analyses displayed herein, and we caution all readers that inclusion of any information on this site does not constitute an endorsement of the truthfulness or accuracy of that information. In particular, this Web site contains complaints and other documents filed in federal and state courts, which make allegations that may or may not be accurate. No reader should, on the basis of information contained in or referenced by this Web site, assume that any of these allegations are truthful.
Go to Search page | Go to Case Index page | Back to Top